RecruitMe Clinical Trial

A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
Feasibility, Safety, and Activity Study of BPX-601 in Subjects With Previously Treated Advanced Solid Tumors
Sponsor:Bellicum Pharmaceuticals, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9974
U.S. Government ID:NCT02744287
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to test what dose of BPX-601 can be given safely with rimiducid to patients with certain types of cancer. The study will look for side effects (good and bad) and how your body responds to the treatment. The study will also see if the treatment helps to stop your cancer from growing or spreading. BPX-601 is a treatment made from your white blood cells (T cells). Your T cells are modified in a laboratory by adding a chimeric antigen receptor gene called a CAR. The CAR recognizes a tumor marker on your cancer. The addition of the CAR is thought to help your own T cells to find and attack your cancer.

Do You Qualify?
Are you 18 years of age or older?YesNo
Are you fully active or at least able to carry out work of a light or sedentary nature?YesNo
Do you have pancreatic ductal adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the prostate?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162